Zejula can now be used as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk after ...
Elahere is a type of targeted therapy called an antibody-drug conjugate. This antibody-drug conjugate is made up of an antibody that is attached to a cancer medicine. Elahere is used to treat a type ...
The overall decline was mainly driven by decreased incidences of epithelial cancers in the ovaries, fallopian tubes, or peritoneum, as well as a decrease in the number of patients diagnosed with ...
Long-Term Follow-Up of Autotransplantation Trials for Multiple Myeloma: Update of Protocols Conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas ...
First Breakthrough Therapy Designation for Daiichi Sankyo and Merck’s raludotatug deruxtecan based on phase 1 trial and REJOICE-Ovarian01 phase 2/3 trial Second Breakthrough Therapy Designation since ...
A new wave of cancer treatments is looking promising for the future of oncologic care. The ovarian cancer drug RC88, which is made by the Chinese biopharmaceutical company RemeGen, received FDA ...
In Ovarian Cancer, Interval Debulking Surgery Leads to Fewer Complications, Does Not Affect Survival
In this systematic review and meta-analysis, researchers examined outcomes among advanced ovarian cancer patients who received interval debulking surgery compared to primary debulking surgery.
New cancer tests at the Mater Hospital are offering fresh hope to patients with some of the most aggressive and hard-to-treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback